<DOC>
	<DOCNO>NCT00298714</DOCNO>
	<brief_summary>There evidence beneficial effect administration angiotensin II type 1 ( AT1 ) receptor antagonists liver fibrosis hepatic stellate cell , experimental model liver fibrosis rodent limited information chronic hepatitis C mild fibrosis . The purpose study investigate effect long-term administration oral Losartan , AT1 receptor antagonist , liver fibrogenesis patient chronic hepatitis C fibrosis F2-F3 ( METAVIR score ) .</brief_summary>
	<brief_title>Effects Losartan Hepatic Fibrogenesis Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>age 35 65 year chronic hepatitis C intermediate fibrosis ( F2F3 Metavir score ) . nonresponder contraindication antiviral therapy . cause liver disease HIV positive alcohol consumption arterial hypertension creatinine &gt; 1.5mg/dL treatment AT1 receptor antagonist angiotensin convert enzyme inhibitor past 12 month . antiviral therapy past 12 month contraindication oral losartan</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
</DOC>